GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Net Income (Discontinued Operations)

Immuron (FRA:ANW) Net Income (Discontinued Operations) : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Immuron Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Immuron's Net Income (Discontinued Operations) for the six months ended in Dec. 2023 was €0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Immuron Net Income (Discontinued Operations) Historical Data

The historical data trend for Immuron's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Net Income (Discontinued Operations) Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Discontinued Operations)
Get a 7-Day Free Trial Premium Member Only - - - - -

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immuron Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Immuron's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANW) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
ASX:CHM ASX:RAD ASX:NOX ASX:PAB ASX:ACR ASX:1AI ASX:NYR ASX:1AD ASX:ATH ASX:BGT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
IMRN:USA ANWA:Germany IMC:Australia
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Website
https://www.immuron.com.au
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines